
Deepinder Goyal on Thursday, 5 November defended his brain-monitoring wearable Temple, calling it a fitness tracker not a medical device, after doctors on X questioned its scientific basis. Goyal said he had spent $30m building Temple, including $20m of his own money, and that a 14-day no-questions-asked return policy proves the product is not a scam.

Goyal added that he left his role as Eternal CEO to focus on Temple and that ‘pre-prints’ of validation studies are coming. Critics, including hepatologist Dr Cyriac Abby Philips, said the device only tracks blood flow in a superficial facial artery, not the brain. Temple is priced at Rs 85,000, with deliveries starting in early 2027.
All four outlets carry Deepinder Goyal’s identical seven-point X thread verbatim, making this uniform coverage of his defence. Business Today, NDTV Profit and Inc42 report his statements with no added critical framing, while Siasat includes the medical experts’ reactions, notably Dr Cyriac Abby Philips calling Goyal’s reply ‘word salad’. The outlets differ only in what they lead with: Business Today opens on the $30m spend, NDTV Profit on Goyal’s hint of undisclosed features, Inc42 on the pre-order price and shipping timeline, and Siasat on the device being a fitness tracker not a medical device. The factual core is common: Goyal insists Temple is not a scam, cites $20m of his own money, a 14-day return policy and imminent pre-prints. The added criticism from doctors appears only in Siasat and Inc42, making those reports more complete on the controversy. Goyal’s 5 November posts are the sole source of all statements attributed to him across the coverage.
Coverage: 4 sources, 4 neutral
Sources (4): businesstoday.in (neutral report), ndtvprofit.com (neutral report), inc42.com (neutral report), siasat.com (neutral report)
This brief was synthesised by AI from the 4 sources linked above, so one read covers every framing they carry. Methodology and corrections.
Update, 6 November 2026: this story now draws on 4 sources.